Cargando…

JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology

Juvenile Idiopathic Inflammatory Myopathies (IIM) are a group of rare diseases that are heterogeneous in terms of pathology that can include proximal muscle weakness, associated skin changes and systemic involvement. Despite options for treatment, many patients continue to suffer resistant disease a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ll Wilkinson, Meredyth G., Deakin, Claire T., Papadopoulou, Charalampia, Eleftheriou, Despina, Wedderburn, Lucy R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466894/ https://www.ncbi.nlm.nih.gov/pubmed/34563217 http://dx.doi.org/10.1186/s12969-021-00637-8

Ejemplares similares

Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care
por: Papadopoulou, Charalampia, et al.
Publicado: (2023)

Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis
por: Wilkinson, Meredyth G Ll, et al.
Publicado: (2023)

Proposal for the development of an international minimal data collection for juvenile dermatomyositis (JDM)
por: McCann, Liza J, et al.
Publicado: (2011)

OA05 Clinical presentation, risk factors and prognosis of MDA5-positive JDM; clinical diversity and red flags
por: McLellan, Kirsty, et al.
Publicado: (2022)

Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
por: Campanilho-Marques, Raquel, et al.
Publicado: (2020)

JDM update September 2014
por: Pilkington, Clarissa
Publicado: (2014)

Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use
por: McCann, Liza J., et al.
Publicado: (2015)

A survey to understand the feelings towards and impact of COVID-19 on the households of juvenile dermato myositis patients from a parent or carer perspective
por: Wilkinson, Meredyth Grace Llewellyn, et al.
Publicado: (2021)

Juvenile dermatomyositis (JDM) sine myositis
por: Schuetz, C, et al.
Publicado: (2011)

Characterising inflammatory markers in two childhood autoimmune diseases (JIA and JDM) pre and post methotrexate
por: Ursu, S, et al.
Publicado: (2011)

How do tissue infiltrating B cells and plasma cells correlate with other inflammatory features in muscle tissue from patients with JDM?
por: Sag, Erdal, et al.
Publicado: (2014)

Calcinosis as a complication of juvenile dermatomyositis (JDM)
por: Clara, Malagón, et al.
Publicado: (2011)

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2019)

What is the mortality of Juvenile Dermatomyositis (JDM) in the modern treatment era
por: Smith, S, et al.
Publicado: (2008)

CD19(+)CD24(hi)CD38(hi) B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α
por: Piper, Christopher J. M., et al.
Publicado: (2018)

Muscle MRI at the time of questionable disease flares in Juvenile Dermatomyositis (JDM)
por: Abdul-Aziz, Rabheh, et al.
Publicado: (2017)

Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist
por: Papadopoulou, Charalampia, et al.
Publicado: (2020)

Case of juvenile dermatomyositis (JDM), thrombotic thrombocytopenic purpura (TTP), and Purtscher retinopathy
por: Goldzweig, Ofra, et al.
Publicado: (2012)

OA29 Blotting-based assays under-detected TIF1-gamma and NXP2 autoantibodies compared to immunoprecipitation in Juvenile Dermatomyositis cohorts
por: Nguyen, Huong D, et al.
Publicado: (2022)

B Cells as a Therapeutic Target in Paediatric Rheumatic Disease
por: Wilkinson, Meredyth G. Ll, et al.
Publicado: (2019)

Sleep, fatigue and quality of life in juvenile idiopathic arthritis (JIA) and Juvenile Dermatomyositis (JDM)
por: Avie, Y Butbul, et al.
Publicado: (2008)

Currently recommended skin scores correlate highly in the assessment of patients with Juvenile Dermatomyositis (JDM)
por: Gebreamlak, Alexander, et al.
Publicado: (2023)

Small Molecule Inhibitors of Interferon‐Induced JAK‐STAT Signalling
por: Thoidingjam, Leishemba K., et al.
Publicado: (2022)

Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children
por: Wang, Xinning, et al.
Publicado: (2021)

The Role of Immunometabolism in the Pathogenesis of Systemic Lupus Erythematosus
por: Robinson, George Anthony, et al.
Publicado: (2022)

Race is a risk factor for calcinosis in patients with JDM – early results from the CARRAnet registry study
por: Hoeltzel, Mark F, et al.
Publicado: (2012)

Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models
por: Deakin, Claire T, et al.
Publicado: (2020)

Sex and Pubertal Differences in the Type 1 Interferon Pathway Associate With Both X Chromosome Number and Serum Sex Hormone Concentration
por: Webb, Kate, et al.
Publicado: (2019)

Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis
por: Deakin, Claire T, et al.
Publicado: (2022)

8.5 Predictors of long-term outcome of Juvenile Dermatomyositis (JDM): a Multicenter, Multinational Study of 490 patients
por: Ferrari, C, et al.
Publicado: (2008)

P11 An unusual case of Systemic Sclerosis/JDM overlap in a child with PAX8-related congenital hypothyroidism
por: Smith, Rachel, et al.
Publicado: (2022)

COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon
por: Hasselbalch, H.C., et al.
Publicado: (2021)

Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study
por: van Dijkhuizen, E. H. Pieter, et al.
Publicado: (2018)

Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren’s Disease
por: Gupta, Sarthak, et al.
Publicado: (2023)

Juvenile Dermatomyositis (JDM) Complicated by Thrombotic Thrombocytopenic Purpura (TTP) and Purtscher's Retinopathy Responsive to Rituximab: Case Report and Literature Review
por: Gullapalli, Keerthi, et al.
Publicado: (2020)

Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools
por: Wienke, Judith, et al.
Publicado: (2018)

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

Development of a benchmarking toolkit for adolescent and young adult rheumatology services (BeTAR)
por: Cai, Ran A., et al.
Publicado: (2019)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Lentiviral Mediated ADA2 Gene Transfer Corrects the Defects Associated With Deficiency of Adenosine Deaminase Type 2
por: Hong, Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r770af4g05o32ub7c4qfbqvjk8